The Keck School of Medicine of USC has received funding from the National Institutes of Health as part of a five-year, $50.3 million “multi-omics” study of human health and disease involving six sites.
FDA fast tracks Alladapt’s multi-food allergy immunotherapy
Share this article Alladapt’s ADP101 is being investigated as a mono- and multi-food allergy oral immunotherapy in patients aged 4-17 years. Image Credit: Ground Picture